We take this responsibility very seriously, which explains why we are continuously centered on self improvement and providing only the highest quality level to our medical partners and the brave donor families who make our function possible,’ said Thomas Cycyota, AlloSource President and CEO. ‘We are proud to have achieved the Foothills Performance Award, and appearance forward to achieving further improvements and awareness through seeking the next two degrees of CPEx.’.. AlloSource receives Foothills Award from CPEx AlloSource, one of the nation’s largest nonprofit providers of epidermis, bone and soft tissue allografts for use in surgical treatments and the world’s most significant processor chip of live cellular bone growth substitutes, today announced it is receipt of the Foothills Award from Colorado Efficiency Excellence , a statewide nonprofit that helps agencies improve overall performance and achieve outcomes.The median progression-free survival was 2.0 months in the TAS-102 group and 1.7 months in the placebo group. The hazard ratio for progression was 0.48 . The result of TAS-102 on progression-free survival was seen in all prespecified subgroups . In the tumor-response population , 8 patients in the TAS-102 group had a partial response, and 1 patient in the placebo group was reported to possess a complete response, resulting in objective response rates of 1 1.6 percent with TAS-102 and 0.4 percent with placebo . Disease control was achieved in 221 individuals in the TAS-102 group and 42 sufferers in the placebo group . The addition of TAS-102 to best supportive care, in comparison with placebo plus best supportive care, resulted in a substantial delay in the worsening of ECOG performance status from the baseline of 0 or one to two 2 or more .